Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment

Table 6

Selected clinical trials using heat shock proteins (HSP).

Reference	Patients	Immunologic response	Clinical response
[177]	𝑛=12; recurrent GBM	—	Median survival: 10.5 mo